Symptom and function profiles of men with localized prostate cancer

Reeve, Bryce B.; Tan, Xianming; Chen, Ronald C.; Usinger, Deborah S.; Pinheiro, Laura C.

doi:10.1002/cncr.31401

Cited by 10 publications

(2 citation statements)

References 34 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, baseline measures of sleep disturbance and sleep-related interference (assessed with the PROMIS SD and PROMIS SRI) were slightly elevated in our study population. The mean baseline PROMIS SD T-score of 56 in our study is higher than the US PROMIS SD Cancer reference value for prostate cancer of 48 [26] and in other studies of the PROMIS SD in individuals with prostate cancer [27,28], including a study of the same PROMIS SD 4-item short form evaluated by telephone interviews in men in North Carolina over 12 months (PROMIS SD T-score = 50) [29]. Thus, our study population likely re ects a subpopulation of prostate cancer patients with greater sleep disturbance.…”

Section: Discussioncontrasting

confidence: 82%

Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer

Peeke,

Billes,

Vetter

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUND This single-arm prospective study evaluated the feasibility of a novel wrist-worn thermal device that applies cooling to the inside of the wrist for management of bothersome hot flashes in prostate cancer survivors. METHODS 57 individuals were enrolled and instructed to use the device as needed for 4 weeks. The primary outcome was thermal device usage (hours and sessions per day). Additional outcomes included the change in patient reported Hot Flash Related Daily Interference Scale (HFRDIS, range 0–10) and Patient Reported Outcomes Measurement Information System Sleep Disturbance 4a (PROMIS SD T-score, range 0-100) and Sleep Related Impairment 8a (PROMIS SRI T-score, range 0-100). Study procedures were conducted remotely from May to Dec 2021 in the US. RESULTS 44 participants completed the study and 39 had retrievable usage data. The mean ± SD age was 67 ± 6 years and 5 ± 5 years since cancer diagnosis. Baseline scores indicated moderate hot flash interference (HFRDIS mean ± SD: 4.3 ± 2.0) and mild sleep disturbance (PROMIS SD: 56.4 ± 6.7). Mean ± SD use of the thermal device was 3.2 ± 2.5 hours/day and 7.6 ± 3.6 sessions/day. Most (67%) participants reported using the device 7 days/nights each week. Statistically significant improvements from baseline at Week 4 were observed for HFRDIS (mean ± SE change: -1.1 ± 0.3), PROMIS SD (-6.0 ± 1.0), and PROMIS SRI (-5.5 ± 1.2) scores (all p < .001). Improvements were also observed in subjective measures of hot flashes and night sweats. The majority (69%) of participants reported that the thermal device was effective at helping them manage hot flashes. No adverse events were reported. CONCLUSIONS Results support the feasibility of using the thermal device for management of bothersome hot flashes in prostate cancer survivors. Future randomized controlled studies are warranted to evaluate patient reported outcomes related to frequency and severity of hot flashes, sleep quality, fatigue, and overall quality of life.

show abstract

Section: Discussioncontrasting

confidence: 82%

Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer

Peeke,

Billes,

Vetter

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Essa diferença não é observada apenas no quesito incidência, mas Research, Society and Development, v. 13, n. 3, e9413345257, 2024 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v13i3.45257 6 também no prognóstico e resposta ao tratamento. Reeve et al (2018) identificou que piores prognósticos e complicações póstratamento tendiam para o grupo composto pelos homens mais pobres e jovens, os quais, em sua maioria, eram negros, com níveis mais baixos de educação, fumantes e portadores de comorbidades. No entanto, Carthon et al (2021) demonstrou que, mesmo quando estratificados em um status socioeconômico igual aos pacientes brancos, o grupo negro apresentou resultados piores.…”

Section: Resultsunclassified

Perfil epidemiológico das neoplasias malignas da próstata no Brasil - Descrição de meia década e a influência da pandemia de SARS-CoV-2

Leonelo,

Rezende,

Álvaro

et al. 2024

RSD

View full text Add to dashboard Cite

O câncer de próstata (CP) é o 2º mais comum em homens. Quando comparado com outros tumores malignos, as disparidades regionais e étnicas continuam a ser uma problemática. O rastreio é realizado através da dosagem de antígeno específico da próstata (PSA) e toque retal, e, se necessário, biópsia. Existem controvérsias em relação ao benefício do rastreamento anual. Dada à importância dos estudos epidemiológicos, este estudo teve como objetivo quantificar os casos notificados e descrever fatores relacionados à taxa de mortalidade e número de internações por CP entre os anos de 2018 e 2023. Os dados foram obtidos no Departamento de Informática do SUS (DATASUS), CID10-C61 (neoplasia maligna da próstata) por local de residência. A população estudada é composta por homens com 40 anos ou mais. A epidemiologia no Brasil se assemelha aos países desenvolvidos, apesar das disparidades regionais. Mais internações ocorreram no Sudeste e menos no Norte, junto com a maior taxa de mortalidade. As desigualdades entre as Regiões são devido a desigualdade de acesso do Estado. Há predominância na taxa de mortalidade aos 80 anos ou mais e maior número de internações aos 60 a 69 anos. Os pardos obtiveram maior número de internação. A maior taxa de mortalidade ocorreu no ano de 2021 e o maior número de internações em 2022 e 2023, podendo ser influenciado pela pandemia de SARS-CoV-2. Analisar o perfil dessa neoplasia é fundamental para direcionar o planejamento das políticas públicas, necessitando de medidas para propiciar acesso mais equitativo às instalações de saúde.

show abstract

Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer

Sibert

Dieng²,

Oesterle³

et al. 2019

World J Urol

View full text Add to dashboard Cite

Symptom and function profiles of men with localized prostate cancer

Cited by 10 publications

References 34 publications

Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer

Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer

Perfil epidemiológico das neoplasias malignas da próstata no Brasil - Descrição de meia década e a influência da pandemia de SARS-CoV-2

Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer

Contact Info

Product

Resources

About